Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesLymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry.
Annals of Rheumatic Diseases, 10/22/09
Mariette X et al. – The two to threefold increased risk of lymphoma in patients receiving anti-TNF therapy is similar as that expected for such patients with severe inflammatory diseases. However, some lymphomas associated with immunosuppression may occur, and the risk of lymphoma is higher with monoclonal-antibody therapy than with soluble-receptor therapy.
Methods- National prospective registry (RATIO) from 2004 to 2006
- All cases of lymphoma in French patients receiving anti-TNF therapy, whatever the indication collected
- Case-control analysis including 2 controls treated with anti-TNF per case and an incidence study of lymphoma with French population used as reference
- Collected 38 cases of lymphoma, 31 non-Hodgkin’s lymphoma (NHL) (26 B-cell and 5 T-cell), 5 Hodgkin’s lymphoma (HL) and 2 Hodgkin’s-like lymphoma
- Epstein-Barr virus (EBV) detected in 2 of 2 Hodgkin’s-like lymphoma, 3 of 5 HL and 1 NHL
- Patients receiving adalimumab or infliximab had higher risk than those treated with etanercept: SIR = 4.1 (2.3–7.1) and 3.6 (2.3–5.6) versus 0.9 (0.4–1.8)
- Exposure to adalimumab or infliximab versus etanercept independent risk factor for lymphoma in case-control study: odds ratio=4.7 (1.3–17.7) and 4.1 (1.4–12.5), respectively
- Sex and age- adjusted incidence rate of lymphoma was 42.1 per 100,000 patient-y
- Standardized incidence ratio (SIR) 2.4 (95% confidence interval [CI] 1.7–3.2)
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
High-Resolution Flow Cytometry: a Suitable Tool for Monitoring Aneuploid Prostate Cancer Cells after TMZ and TMZ-BioShuttle Treatment
International Journal of Medical Sciences , 11/25/09
Comparative study of control selection in a national population -based case-control study: Estimating risk of smoking on cancer deaths in Chinese men
International Journal of Medical Sciences , 11/25/09
Prospective studies of dietary alpha-linolenic acid intake and prostate cancer risk: a meta-analysis
Cancer Causes and Control, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor